Founded in 1999,  Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox.  The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development.

    * High-throughput ADME screening
    * Customised ADME assays
    * In silico ADME predictive modeling
    * In vitro toxicology

Life Sciences

Cyprotex

Dr. Anthony Baxter

Phil Butler

Paul Walker

Stephen Madden

Research and Development Scientists

Leadership Team

Business Development Team

Research and Development

Teams at Cyprotex

Research and Development Scientists

Leadership Team

Business Development Team

Research and Development